May 04, 2023 8:00am EDT Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 02, 2023 4:30pm EDT Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Apr 17, 2023 8:00am EDT Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alfa (PRS-343) At 2023 AACR Annual Meeting
Mar 29, 2023 7:00am EDT Pieris Pharmaceuticals Reports Full-Year 2022 Financial Results and Business Updates
Mar 24, 2023 5:00pm EDT Pieris Pharmaceuticals to Host Year End 2022 Investor Call and Provide Corporate Update on March 29, 2023
Jan 10, 2023 8:00am EST Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)
Nov 02, 2022 7:00am EDT Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 01, 2022 9:15am EDT Pieris Pharmaceuticals Announces Dosing of First Subject in Phase 1 Trial of Inhaled CTGF Inhibitor PRS-220
